Zer, Alona <br/><br/>
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.  [electronic resource] 

 -  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer  Mar 2016 
 - 312-23 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1556-1380 
<br/><br/><label>Standard No.: </label>10.1016/j.jtho.2015.11.010  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Prognosis<br/>Protein Kinase Inhibitors--therapeutic use<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Randomized Controlled Trials as Topic